Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial

Lignende værker

• HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
  af: Song, Yan, et al.
  Udgivet: (2020)
• A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
  af: Uronis, Hope E., et al.
  Udgivet: (2013)
• Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
  af: Haiping Jiang, et al.
  Udgivet: (2020-08-01)
• Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
  af: Jiang, Haiping, et al.
  Udgivet: (2020)
• HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
  af: Jibin Zhang, et al.
  Udgivet: (2020-01-01)